The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Evaluation of mRNA-1273 SARS-CoV-2 Vaccine in Adolescents
Open accessAbstract
BACKGROUND: The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown. METHODS: In this ongoing phase 2-3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 μg in each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of mRNA-1273 in adolescents and the noninferiority of the immune response in adolescents as compared with that in young adults (18 to 25 years of age) in a phase 3 trial. Secondary objectives included the efficacy of mRNA-1273 in preventing Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection. RESULTS: A total of 3732 participants were randomly assigned to receive mRNA-1273 (2489 participants) or placebo (1243 participants). In the mRNA-1273 group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively); in the placebo group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 34.8% or 30.3%, respectively), headache (in 38.5% and 30.2%, respectively), and fatigue (in 36.6% and 28.9%, respectively). No serious adverse events related to mRNA-1273 or placebo were noted. The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08 (95% confidence interval [CI], 0.94 to 1.24), and the absolute difference in serologic response was 0.2 percentage points (95% CI, -1.8 to 2.4), which met the noninferiority criterion. No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group. CONCLUSIONS: The mRNA-1273 vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in preventing Covid-19. (Funded by Moderna and the Biomedical Advanced Research and Development Authority; Teen COVE ClinicalTrials.gov number, NCT04649151.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“94.1% efficacy at preventing COVID-19 illness, including severe disease in participants 18 years or older995% efficacy in 12- to 17-year olds84”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [84]
In the citing paper
“with similar immune responses among adolescents aged 12 to 17.410,412–414”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [412]
In the citing paper
“In a phase III clinical trial involving 30,420 people, participants aged 18 or older were given two doses of 100 μg of mRNA-1273 with a 28-day interval, and vaccine efficacy was 94.1% (Table 5)”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [412]
In the citing paper
“In 12- to 17-year-olds, mRNA-1273 showed 95% vaccine efficacy and had an acceptable safety profile.84”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H. P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,774
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523
Self-citationFamily violence and COVID‐19: Increased vulnerability and reduced options for support
Usher, K., Bhullar, N., Durkin, J., Gyamfi, N., & Jackson, D. (2020) · International Journal of Mental Health Nursing · doi:10.1111/inm.12735 · Cited by 979
Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults
Viner, R., Mytton, O. T., Bonell, C. P., Meléndez‐Torres, G. J., Ward, J., Hudson, L. D., Waddington, C. S., Thomas, J., Russell, S., van der Klis, F. R. M., et al. (2020) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.4573 · Cited by 893
Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents
Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107456 · Cited by 889
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103916 · Cited by 673
Self-citationKim, L., WHITAKER, M. D., O’Halloran, A. C., Kambhampati, A. K., Chai, S. J., Reingold, A. L., Armistead, I., Kawasaki, B., Meek, J. I., Yousey-Hindes, K. M., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e3 · Cited by 513
Age groups that sustain resurging COVID-19 epidemics in the United States
Monod, M., Blenkinsop, A., Xi, X., Hebert, D. J., Bershan, S., Tietze, S., Baguelin, M., Bradley, V. C., Chen, Y., Coupland, H., et al. (2021) · Science · doi:10.1126/science.abe8372 · Cited by 335
Suffering in silence: How COVID-19 school closures inhibit the reporting of child maltreatment
Baron, E. J., Goldstein, E. G., & Wallace, C. T. (2020) · Journal of Public Economics · doi:10.1016/j.jpubeco.2020.104258 · Cited by 328
Incidence and secondary transmission of SARS-CoV-2 infections in schools
Zimmerman, K. O., Akinboyo, I. C., Brookhart, M. A., Boutzoukas, A. E., McGann, K. A., Smith, M. J., Maradiaga Panayotti, G., Armstrong, S. C., Bristow, H., Parker, D., et al. (2021) · Pediatrics · doi:10.1542/peds.2020-048090 · Cited by 223
Chu, L., McPhee, R. A., Huang, W., Bennett, H., Pajón, R., Nestorova, B., & Leav, B. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.007 · Cited by 223
Self-citationPenner, J., Abdel‐Mannan, O., Grant, K., Maillard, S., Kučera, F., Hassell, J. K., Eyre, M., Berger, Z. E., Hacohen, Y., Moshal, K. L., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00138-3 · Cited by 205
Swedo, E. A., Idaikkadar, N., Leemis, R. W., Dias, T. P., Radhakrishnan, L., Stein, Z., Chen, M. W., Agathis, N. T., & Holland, K. M. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6949a1 · Cited by 170
FDA approves the Pfizer-BioNTech COVID-19 vaccine
Satyanarayana, M. (2021) · C&EN Global Enterprise · doi:10.47287/cen-09931-buscon1 · Cited by 127
Havers, F. P., WHITAKER, M. D., Self, J. L., Chai, S. J., Kirley, P. D., Alden, N. B., Kawasaki, B., Meek, J. I., Yousey-Hindes, K. M., Anderson, E. J., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7023e1 · Cited by 110
Hobbs, C. V., Martin, L., Kim, S. S., Kirmse, B., Haynie, L., McGraw, S., Byers, P., Taylor, K. G., Patel, M. M., Flannery, B. L., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e3 · Cited by 84
Chua, G. T., Wong, J. S. C., Lam, I. C. S., Ho, P. K., Chan, W. H., Yau, F. Y. S., Duque, J. S. R., Ho, A. C. C., Siu, K. K., Cheung, T. W. Y., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8824 · Cited by 64
Flagged first, then by citations
Research works printed but not linked: 1
- 10.1056/NEJMoa2027906 · DOI · Paper page
Cited by
Sorted by citations
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641
Self-citationAdvances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601
Efficacy and safety of COVID-19 vaccines
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B. S., Probyn, K., Villanueva, G., Henschke, N., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015477 · Cited by 310
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308
Ssentongo, P., Ssentongo, A. E., Voleti, N., Groff, D., Sun, A., Ba, D. M., Nunez, J., Parent, L. J., Chinchilli, V. M., & Paules, C. I. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07418-y · Cited by 260
Metadata
- Authors
- Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R.
- Affiliations
- From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).
- Corresponding author
- McPhee, Roderick
- ORCID
- Girard, Bethany
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2241-2251
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8385554
- OpenAlex
- W3189261358
- Cited by
- 377
- References
- 20
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 54 · 2023: 87 · 2022: 160 · 2021: 35
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, adolescents, vaccine safety, immunogenicity, neutralizing antibodies, non-inferiority, vaccine efficacy, asymptomatic infection, adverse events, serological response, pseudovirus neutralization assay, Omicron variant, Omicron BA.1
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, Vaccine Efficacy, 2019-nCoV Vaccine mRNA-1273, Adolescent, Antibodies, Viral, Child, Female, Humans, Male, Single-Blind Method, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
